...
首页> 外文期刊>Bulletin of Clinical Psychopharmacology >Intracellular Adhesion Molecule (ICAM-1), Vascular Cell Adhesion Molecule (VCAM-1) and E-selectin levels in first episode schizophrenic patients
【24h】

Intracellular Adhesion Molecule (ICAM-1), Vascular Cell Adhesion Molecule (VCAM-1) and E-selectin levels in first episode schizophrenic patients

机译:首发精神分裂症患者的细胞内粘附分子(ICAM-1),血管细胞粘附分子(VCAM-1)和E-选择素水平

获取原文

摘要

Objectives: The aim of this study was to compare the levels of intracellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (V-CAM-1) and E-selectin, which are considered as possible biological determinants in prognosis and progression of atherosclerosis, in schizophrenia patients pre-and post-treatments and healthy controls. Methods: In Erenk?y Research and Training Hospital for Mental and Neurological Disorders, drug naive 50 patients with a diagnosis of first episode schizophrenia according to the DSM-IV-TR diagnostic criteria, and a control group consisting of 50 healthy volunteers were enrolled in this study. Plasma levels of ICAM-1, VCAM-1, E-selectin, fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides of the patients were measured at the beginning of the study (n = 50) and at the end of the third month (n = 39), and compared. The same biochemical parameters of the controls were measured at only the beginning of the study. In order to assess the termination of the acute episode, the Positive Symptoms Assessment Scale (SAPS) and Negative Symptoms Assessment Scale (SANS) were applied to the patients at the beginning of the study and at the end of the third month. Results: The average age of patients experiencing their first episode of schizophrenia was 30.14±7.50. The initial ICAM-1 levels of the patients were lower than those of the control group (t= 3.41, p=.001), and increased after treatment (t=-6.73 p< .001), while there was no difference in the VCAM-1 and E-selectin levels of the patients and controls (t=-1.23, p=.223; t=-0.32 p=.750, respectively). Also, post-treatment VCAM-1 levels were lower than the initial levels (t=7.17, p<.001). The average levels of fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were similar in the control and patient groups, while a significant increase was observed in triglyceride levels of patients with schizophrenia after treatment (t=-3.19, p=.003). Conclusion: The levels of cellular adhesion molecules of individuals experiencing a first episode of schizophrenia were not different from controls, with the exception of the levels of ICAM-1. Cellular adhesion molecules were observed to act differently, as re?ected by the recorded plasma levels during treatment. The antipsychotics used in the treatment of schizophrenia increased ICAM-1 and decreased VCAM-1. This study is limited by the size of the patient population, the lack of treatment control, the possibility that the disease may not have a homogeneous structure and other possible unknown confounding factors.
机译:目的:本研究的目的是比较细胞内粘附分子(ICAM-1),血管细胞粘附分子(V-CAM-1)和E-选择素的水平,它们被认为是预后和进展的生物学决定因素。精神分裂症患者的治疗前后动脉粥样硬化和健康对照。方法:在Erenk?y精神和神经疾病研究训练医院中,根据DSM-IV-TR诊断标准对50例初发精神分裂症的初次确诊的患者进行药物治疗,并纳入由50名健康志愿者组成的对照组这项研究。在研究开始(n = 50)和结束时测量患者的ICAM-1,VCAM-1,E-选择素,空腹血糖,总胆固醇,LDL胆固醇,HDL胆固醇和甘油三酸酯的血浆水平第三个月(n = 39),然后进行比较。仅在研究开始时测量对照的相同生化参数。为了评估急性发作的终止,在研究开始时和第三个月末对患者应用了阳性症状评估量表(SAPS)和阴性症状评估量表(SANS)。结果:第一次精神分裂症患者的平均年龄为30.14±7.50。患者的初始ICAM-1水平低于对照组(t = 3.41,p = .001),并在治疗后升高(t = -6.73 p <.001),而在治疗后无差异。患者和对照组的VCAM-1和E-选择素水平(分别为t = -1.23,p = .223; t = -0.32 p = .750)。而且,治疗后的VCAM-1水平低于初始水平(t = 7.17,p <.001)。对照组和患者组的空腹血糖,总胆固醇,低密度脂蛋白胆固醇,高密度脂蛋白胆固醇和甘油三酸酯的平均水平相似,而治疗后精神分裂症患者的甘油三酸酯水平显着升高(t = -3.19,p = .003)。结论:发生精神分裂症首发的个体的细胞粘附分子水平与对照组无差异,但ICAM-1水平除外。如治疗期间记​​录的血浆水平所反映的,观察到细胞粘附分子的行为不同。用于精神分裂症治疗的抗精神病药可增加ICAM-1并降低VCAM-1。这项研究受到患者人数,缺乏治疗控制,疾病可能不具有均一结构的可能性以及其他可能未知的混杂因素的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号